

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials⦠read more
Healthcare
Biotechnology
22 years
USD
Exclusive to Premium users
$0.93
Price+9.19%
$0.07
$61.294m
Small
-
Premium
Premium
-29570.7%
EBITDA Margin-30109.8%
Net Profit Margin-29970.7%
Free Cash Flow Margin-29570.7%
EBITDA Margin-30109.8%
Net Profit Margin-29970.7%
Free Cash Flow Margin$525k
-11.5%
1y CAGR+5.1%
3y CAGR+10.4%
5y CAGR-$44.762m
+2.4%
1y CAGR-2.7%
3y CAGR-3.8%
5y CAGR-$0.67
+2.9%
1y CAGR+9.4%
3y CAGR+5.9%
5y CAGR$34.709m
$49.172m
Assets$14.463m
Liabilities$646k
Debt1.3%
-
Debt to EBITDA-$37.461m
+1.3%
1y CAGR-6.4%
3y CAGR-2.5%
5y CAGR